MMSI Merit Medical Systems Inc.

Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).

To access the conference call, please pre-register using the following . Registrants will receive confirmation with dial-in details.

A live webcast and slide deck can be accessed using this . A link to both register for the conference call and view the webcast will be made available at

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.

Contacts: 
  
PR/Media Inquiries:Investor Inquiries:
Sarah Comstock

Mike Piccinino, CFA, IRC

Merit MedicalICR Healthcare
 
  


EN
03/07/2025

Underlying

MMSIMerit Medical Systems Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Systems To Announce Second Quarter 2025 Results On July ...

Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access ...

15h 1 EN
Free Trial
MMSI Merit Medical S...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

MMSI MERIT MEDICAL SYSTEMS INC.
06/10/25 June 10, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

May 20, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

May 6, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch